miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· June 22, 2026

Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals

View original at globenewswire.com
Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals Neither the Company nor its subsidiaries are under investigation by any regulatorUrges CIRO to investigate potentially manipulative or deceptive trading activity in Abaxx’s common sharesRetains leading U.S…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • New exchange markets exhibit natural growth patterns including low open interest relative to volume and trading dominated by incentive program participants building initial liquidity

    60% confidence
  • Through June 19, 2026, the average daily volume on Abaxx Exchange for June was 16,846 contracts per day, a 12% increase from May's 15,092

    60% confidence
  • Average daily open interest on Abaxx Exchange for June was 1,343, a 232% increase from May's 405

    60% confidence
  • None of the participants in Abaxx Exchange's market making and liquidity provider programs are undisclosed related parties

    60% confidence
  • Viceroy's reports amount to a short-and-distort campaign with the sole purpose of profiting from a decline in Abaxx's common share price at the expense of long-term shareholders

    60% confidence
  • Current cash is sufficient to fund operational plans for approximately the next seven quarters without raising additional funds

    60% confidence
  • Wash trading is illegal and not permitted on Abaxx Exchange pursuant to Rule 508 in the Exchange's rulebook

    60% confidence
  • Abaxx Exchange has a robust market surveillance program that actively monitors trading for signs of wash trading or market manipulation in alignment with regulatory requirements

    60% confidence
  • There are now 11 ISVs connected to Abaxx Exchange with 5 more in the pipeline

    60% confidence
  • The current net cash burn rate has averaged C$12.3 million over the past 2 completed quarters

    60% confidence
  • The Company holds more than C$97 million in cash and cash equivalents as of June 2026

    60% confidence
  • There are now 7 clearing firms connected to Abaxx Exchange with 14 more in the pipeline

    60% confidence
  • There are currently 22 brokers connected to Abaxx Exchange with 10 more in the pipeline

    60% confidence
  • Neither the Company nor its subsidiaries are under investigation by any regulator

    60% confidence
  • Suspected violations are subject to Abaxx Exchange's disciplinary proceedings under Rule 209, which can include reporting to regulators and suspension or termination of offending parties

    60% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com